levodopa/carbidopa high dose (ND0612H) / Mitsubishi Tanabe  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
levodopa/carbidopa high dose (ND0612H) / Mitsubishi Tanabe
NCT02782481 / 2016-002033-30: A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Withdrawn
3
0
RoW
ND0612, Levodopa/Carbidopa solution, Placebo, Placebo solution
NeuroDerm Ltd.
Parkinson's Disease
10/18
10/18
NCT03462043 / 2017-002780-17: A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

Withdrawn
3
0
Europe
ND0612, CLES
NeuroDerm Ltd.
Parkinson
11/18
12/18
BouNDless, NCT04006210 / 2018-004156-37: Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

Active, not recruiting
3
381
Europe, US, RoW
ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, IR-LD/CD, Placebo for Oral IR-LD/CD, Placebo for IR-LD/CD
NeuroDerm Ltd.
Parkinson's Disease
11/22
02/27

Download Options